DynaMed and DynaMedex cost: pricing, access, and how they compare to UpToDate

DynaMedex is DynaMed plus the drug database. That is the whole distinction, and it is worth stating plainly because the two names differ by two letters and the vendor's own materials use them interchangeably in places.

DynaMed on its own is the evidence-based disease reference: topic summaries reviewed daily against the literature by physicians and methodologists, with evidence grades attached and links back to the primary sources. DynaMedex takes that content and folds in Micromedex drug information and its advanced search, in what EBSCO calls a single integrated workflow. EBSCO positions DynaMedex as the most comprehensive resource in the suite, which in practice means it is the one they would rather sell you.

For a buyer the question is narrower than the marketing makes it sound. If your team's unanswered questions are mostly "how should this be managed", DynaMed covers them. If a large share are "what does this drug do to that one, and at what dose in renal impairment", you want the Micromedex layer, and DynaMedex is how EBSCO sells it to you.

Almost every serious point-of-care product in US medicine is a disease reference wrapped around a drug database that somebody else built, and the wrapping is where the money goes. DynaMedex carries Micromedex content, which Merative also sells on its own. UpToDate's drug monographs come from Lexidrug, formerly Lexicomp, from its own parent Wolters Kluwer.

That has a direct consequence at renewal. Organizations routinely license a disease reference and a standalone drug database, and then discover the two overlap substantially. If you already hold DynaMedex, ask what a separate Micromedex subscription is still adding. If you hold UpToDate and a drug database, the same question applies in reverse, which is the argument we lay out in the UpToDate vs Lexicomp comparison. Overlap is the one piece of leverage a buyer reliably has in a market with no published prices.

There is one more gate worth reading carefully. Dyna AI, the AI search layer, is not sold separately, and EBSCO states that its availability depends on your subscription and access level. A paid seat does not automatically carry it. If the AI is the reason you are upgrading, put it in the quote rather than assuming.

Because the revenue sits in institutional contracts, and those are negotiated one organization at a time. A public rate card would set an anchor for every one of those negotiations, in the buyer's favor. So there is no store page, only a contact form.

The pattern is consistent enough across this market to be a rule. UpToDate publishes nothing at any tier. Micromedex publishes nothing. DynaMed and DynaMedex publish nothing. All four are sold to procurement departments. Meanwhile Lexidrug carries a plainly visible $29.99 a month on the App Store and Epocrates+ shows $179.99 a year, because those are bought by one clinician with a credit card. Price transparency in this category tracks who signs the check, not how good the product is. We took the same measurements across the whole market in the UpToDate subscription cost guide.

The practical effect on you is that two comparable hospitals can pay materially different amounts for the same seats, and neither will ever find out. That is not a scandal, it is just how quote-only markets work, and it is why walking in with your seat count and your overlap analysis matters more here than in almost any other software purchase. We cover that process in detail in the institutional license and enterprise pricing guide.